biocon vikash presentation
Post on 03-Apr-2018
253 Views
Preview:
TRANSCRIPT
-
7/28/2019 Biocon Vikash presentation
1/28
BIOCON LTD: Building a biotech powerhouseFrom bottom to TOP
BY-Manoj DubeyKanishka PathakVikash ThakurVeer chhatarashalAkhilesh kumar
Shadab Alam
-
7/28/2019 Biocon Vikash presentation
2/28
Industry Outlook
The biotech industry in India is expected to showsalubrious growth rates in coming years, and is projectedto enjoy a CAGR of around 20% between FY2012 &FY2013, says RNCOS in its latest research report,
"Booming Biotech Market in India".
Future of the industry remains pleasantly buoyantdespite the lack of venture funding and stringentregulations in the country.
http://www.rncos.com/Report/IM110.htmhttp://www.rncos.com/Report/IM110.htm -
7/28/2019 Biocon Vikash presentation
3/28
Leading Players
Name Year ofestablishment SegmentRevenue(in milliondollars)
Serum Instituteof India
1966 Bio-pharma 1870
Panacea Biotec 1984 Bio -pharma 640
Biocon ltd 1978
Bio-pharma/Bio
serivces/Bio-industrial
533.91
NicholasPiramal
1988 Bio-pharma 106.95
Novo Nordisk 1973 Bio-agri 80.07
-
7/28/2019 Biocon Vikash presentation
4/28
About BIOCON The first and largest biotech company in India, started in 1978 formulating
industrial enzymes provided by an Irish company.
Biocon retains its roots in the world markets for food and industrial enzymes.
It also has turned its fermentation technology to the manufacture of drugs,developing a pipeline of statins and winning U.S. FDA to market generic
lovastatin for cholesterol reduction. Biocon also has created contract drugdiscovery, clinical trials, genomics and chemistry research units and sistercompanies.
Biocon's Syngene unit has 150 scientists working on drug discovery, chemicalsynthesis, molecular biology.
Biocon is ranked among the top 20 global biotechnology companies (Med AdNews). Biocon is the 7th largest biotech employer in the world (Med AdNews).
-
7/28/2019 Biocon Vikash presentation
5/28
Mile Stones
1978 - Incorporated as JV-Biocon Biochemicals Ltd & Kiran Mazumdar-Shaw.
1979 - First Indian company to manufacture and export enzymes to USA and Europe.
1989 - Unilever plc. acquires Biocon Biochemicals Ltd.
1993 - Establishes Syngene International Pvt. Ltd. ,a Custom Research Company(CRC).
1996 - The commercial success of Biocon's proprietary fermentation plant leads to a 3-
fold expansion; enters biopharmaceuticals and statins. 1998 - Unilever agrees to sell its shareholding in Biocon to the Indian promoters.
Biocon becomes an independent entity
2000 - Establishes Clinigene, India's first Clinical Research Organisation (CRO).
2003First company worldwide to develop human insulin (Pichia expression system).
2004Issues IPO which valued the company at $1.1 bn.
2006 - Inaugurates Biocon Biopharmaceuticals, India's largest multi-product Biologicsfacility ; India's first anti-cancer drug, BIOMAb EGFR.
2008 - Biocon acquires 70% stake in German pharmaceutical company, AxiCorpGmbH
2009 - Biocon launches BASALOGTM - long lasting basal insulin for Type 1 & Type 2Diabetics.
-
7/28/2019 Biocon Vikash presentation
6/28
Its subsidiaries
SyngeneInternationalLtd (100%)
ClinigeneInternational
ltd (100%)
BioconBioPharmaceuticals
Pvt ltd (100%)
NeoBiocon FZLLC (50%)
Biocon SDN.BHD (100%)
Biocon SA(100%)
BioconResearch ltd
(100%)
-
7/28/2019 Biocon Vikash presentation
7/28
The Visionary
Born on 23 March 1953 in Bangalore
Post grad. Zoology from Bangalore university 1972
Master brewer from Ballarat University in Melbourne 1975
Trainee brewer in Carlton & United Beverages in 1975-77 First Indian woman brew master
Joined Biocon biochemical Ltd. Ireland in 1978
Dr. Kiran M. Shaw In 1978 founded Biocon India
After wards she never turned back and reached to the apex of BIOTECHindustry in India ,Currently she is richest women in India.
-
7/28/2019 Biocon Vikash presentation
8/28
Conti
-
7/28/2019 Biocon Vikash presentation
9/28
Products
Products
Enzymes
IndustrialFood
Feed
Biopharmaceuticals
80% turnoverStatins major. product
Clinical trialsHandled byClinegen
Focus on Phase Iand Phase IIItrials
Custom ResearchHandled by Syngene
Synthetic chemistryand MolecularBiology are towareas covered
Drug
Discovery
-
7/28/2019 Biocon Vikash presentation
10/28
Problems
In initial Stages - Financing regular operations
Approached financial institutions, but turned down, coz:
Biotechnology is a new word
No assets for company
Woman entrepreneur is a rare word Recruiting staff
Current (According to case study)-
Spread its business to research and development and drug discoveryareas
-
7/28/2019 Biocon Vikash presentation
11/28
SWOT ANALYSIS
Strength: Low Price : Insugen price of $ 2.5 per 10 ml
Debt free & cash rich status
Rich & expanding new drug pipeline
Biocons R&D expertise Biocon has a patent fermentation process
Weakness: Statin (which lower the amount of cholesterol in
blood) dependentdont have patent for statin molecules
Limited clientele
Revenue profile is highly concentrated
-
7/28/2019 Biocon Vikash presentation
12/28
Conti
Opportunity:Market potential : Statins market likely to grow at a rate
of 20% in the next yearIndia has the most quantity & diversity type of diabetesGreat manufacturing capabilitiesInsulin injections are a painful process
Expiration of patents worldwide
Threats:-Regulatory riskCompetitive threats
Raw material & fuel costs are linked to global commoditypricesDollar depreciation rising personnel costs & increasing
operational overheads on account of oil & powerWockhardt already has launched insulin product in
market so, Biocon has to face serious competition
-
7/28/2019 Biocon Vikash presentation
13/28
Market share
-
7/28/2019 Biocon Vikash presentation
14/28
-
7/28/2019 Biocon Vikash presentation
15/28
Financials
-
7/28/2019 Biocon Vikash presentation
16/28
-
7/28/2019 Biocon Vikash presentation
17/28
Current Ratio
-
7/28/2019 Biocon Vikash presentation
18/28
Asset turnover ratio
0
0.2
0.4
0.6
0.8
1
1.2
1.4
2007 2008 2009 2010 2011
Asset Turnover Ratio
Asset Turnover Ratio
-
7/28/2019 Biocon Vikash presentation
19/28
Net Profit Margin
0
5
10
15
20
25
30
35
40
45
50
2007 2008 2009 2010 2011
Net Profit Margin(%)
Net Profit Margin(%)
-
7/28/2019 Biocon Vikash presentation
20/28
Earning per share
-
7/28/2019 Biocon Vikash presentation
21/28
From the ratio analysis we can say that the firmhas a favorable financial status to spread its
business to research and development and drugdiscovery areas
-
7/28/2019 Biocon Vikash presentation
22/28
BCG ANALYSIS
BIOCON can be put in the BCG STARS as the company had veryhigh growth opportunities and high market share.
-
7/28/2019 Biocon Vikash presentation
23/28
Strategies
No commodity production in beginning due to lack ofinfrastructure Diversification rather than expansion Formed Helix (antibiotic prod.) Formed Syngene, Clinigene (R&D in fermentation)
Biocon Quest to produce drugs in mass. Strategic alliances with 20 companies around globe. Eg
AXICORP , DEAKIN UNIVERSITY Fully integrated business model
Enzymes produced & sold as industrial intermediaries Customer (staying with buyers processing line helping them
obtain desired result from the enzyme) Created an image of a reliable company able to give highly
competent technical products & support
-
7/28/2019 Biocon Vikash presentation
24/28
Major Competitors
Cadila Healthcare Divi's Lab
Lupin Ltd.
Glenmark Pharma
GlaxoSmithKline Phar Aurobindo Pharma
Dr. Reddy's Labs
Fortis Healthcare Sun Pharma.
Cipla
-
7/28/2019 Biocon Vikash presentation
25/28
CSR
Arogya Raksha Yojana (ARY) HealthcareInitiatives
Primary Health Education & Implementation
Infrastructure: constructing school buildings
(including a performance stage, flooring,classrooms),creches, sanitary facilities and watersupply connections.
Under phase I of the sanitation program, 700
toilets have been built in Huskur.
-
7/28/2019 Biocon Vikash presentation
26/28
Current Status India's Biocon expects to launch psoriasis drug by end FY13MUMBAI, July 26 - Biocon, India's top listed biotechnology company, expects to
launch Itolizumab, a drug to treat psoriasis, by end of the current fiscal year India's Biocon Q1 net up 12.5 pctJuly 26 - Three months ended June 30 , Net Profit 788.0 vs 700.5 Total Income5,926.0 vs 4,635.2 Results are consolidated. NOTE: Biocon Ltd is India's top-listed
biotechnology company. Ampio signs deal with Biocon unit on sexual dysfunction drugREUTERS - Ampio Pharmaceuticals Inc signed a deal with Syngene, a unit of
Bangalore-based Biocon Ltd , to produce its experimental drug for prematureejaculation and erectile dysfunction, sending its shares up 23 percent. Biocon to develop nutrition products for IndiaREUTERS - Abbott Laboratories has partnered Indian biotechnology companyBiocon Ltd to develop nutrition products for India, as the U.S. drugmaker steps upits push to tap a potentially big market. Biocon Q4 beats forecast, shares rise
An expected licencing income helped Biocon, India's top-listed biotechnologycompany, post better-than-expected quarterly profit and lift its shares more than 4percent, but it said the global business outlook remained uncertain. Pfizer scraps insulin deal with BioconPfizer Inc , the world's largest drugmaker, has scrapped a deal to sell insulinproducts made by Biocon Ltd , leaving India's biggest biotechnology company
without a partner to sell the drugs in key markets such as the United States.
http://in.reuters.com/article/2012/07/26/biocon-psoriasis-drug-idINL4E8IQ19720120726?type=companyNewshttp://in.reuters.com/article/2012/07/26/biocon-results-idINL4E8IQ11Z20120726?type=companyNewshttp://in.reuters.com/article/2012/07/02/ampiopharmaceuticals-zertane-syngene-bio-idINDEE8610CZ20120702?type=companyNewshttp://in.reuters.com/article/2012/05/03/abbott-biocon-partnership-idINDEE84204A20120503?type=companyNewshttp://in.reuters.com/article/2012/04/27/india-biocon-results-idINDEE83Q05C20120427?type=companyNewshttp://in.reuters.com/article/2012/03/13/pfizer-biocon-idINDEE82C01K20120313?type=companyNewshttp://in.reuters.com/article/2012/03/13/pfizer-biocon-idINDEE82C01K20120313?type=companyNewshttp://in.reuters.com/article/2012/03/13/pfizer-biocon-idINDEE82C01K20120313?type=companyNewshttp://in.reuters.com/article/2012/04/27/india-biocon-results-idINDEE83Q05C20120427?type=companyNewshttp://in.reuters.com/article/2012/04/27/india-biocon-results-idINDEE83Q05C20120427?type=companyNewshttp://in.reuters.com/article/2012/05/03/abbott-biocon-partnership-idINDEE84204A20120503?type=companyNewshttp://in.reuters.com/article/2012/05/03/abbott-biocon-partnership-idINDEE84204A20120503?type=companyNewshttp://in.reuters.com/article/2012/07/02/ampiopharmaceuticals-zertane-syngene-bio-idINDEE8610CZ20120702?type=companyNewshttp://in.reuters.com/article/2012/07/02/ampiopharmaceuticals-zertane-syngene-bio-idINDEE8610CZ20120702?type=companyNewshttp://in.reuters.com/article/2012/07/02/ampiopharmaceuticals-zertane-syngene-bio-idINDEE8610CZ20120702?type=companyNewshttp://in.reuters.com/article/2012/07/26/biocon-results-idINL4E8IQ11Z20120726?type=companyNewshttp://in.reuters.com/article/2012/07/26/biocon-results-idINL4E8IQ11Z20120726?type=companyNewshttp://in.reuters.com/article/2012/07/26/biocon-results-idINL4E8IQ11Z20120726?type=companyNewshttp://in.reuters.com/article/2012/07/26/biocon-psoriasis-drug-idINL4E8IQ19720120726?type=companyNewshttp://in.reuters.com/article/2012/07/26/biocon-psoriasis-drug-idINL4E8IQ19720120726?type=companyNews -
7/28/2019 Biocon Vikash presentation
27/28
Why Dr. K.M. Shaw is an Entrepreneur No man was willing to work for her.
Accountant left at the first sign ofanother job.
DETERMINATION
She started her Business in relativelynew and innovative field.
When bank refused loans to Kiran, she
went against all odds as a belief thatwomen can be an entrepreneur.
CONFIDENCE
Focused on R&D and innovativestrategy to produce new products.
Made her employees to think
innovative
INNOVATION
Company had no assets. Biotechnology was a new concept to
Indians. Woman entrepreneur was a new word.
RISK TAKER
-
7/28/2019 Biocon Vikash presentation
28/28
THANK YOU
top related